Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cross-bridge Cycle01:26

Cross-bridge Cycle

123.5K
As muscle contracts, the overlap between the thin and thick filaments increases, decreasing the length of the sarcomere—the contractile unit of the muscle—using energy in the form of ATP. At the molecular level, this is a cyclic, multistep process that involves binding and hydrolysis of ATP, and movement of actin by myosin.
123.5K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K
Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

2.5K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.5K
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

2.1K
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
2.1K
Chemical Synapses01:26

Chemical Synapses

12.1K
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
12.1K
Chemical Synapses01:26

Chemical Synapses

5.2K
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
5.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ECAS-Based Neuropsychological Phenotyping in Amyotrophic Lateral Sclerosis: A Retrospective Study Comparing Different Algorithms.

Neurology and therapy·2026
Same author

Correction: Decoding distinctive features of plasma extracellular vesicles in amyotrophic lateral sclerosis.

Molecular neurodegeneration·2026
Same author

Environmental Personal Exposure Clusters to Investigate Multiple Sclerosis and Amyotrophic Lateral Sclerosis Progression.

Studies in health technology and informatics·2026
Same author

Beyond the surface: Exploring differing aspects of wishes to hasten death in patients with amyotrophic lateral sclerosis.

Palliative & supportive care·2026
Same author

"Silent Echoes of the Day: Dream Content Analysis in Amyotrophic Lateral Sclerosis".

Brain and behavior·2026
Same author

King's stages of amyotrophic lateral sclerosis: an 18F-FDG-PET study of brain connectivity.

Brain : a journal of neurology·2026
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
See all related articles

Related Experiment Video

Updated: Mar 1, 2026

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
15:48

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

Published on: July 29, 2007

10.1K

Amyotrophic lateral sclerosis.

Michael A van Es1, Orla Hardiman2, Adriano Chio3

  • 1Department of Neurology, Brain Center Rudolf Magnus, University Medical Center Utrecht, the Netherlands.

Lancet (London, England)
|May 30, 2017
PubMed
Summary
This summary is machine-generated.

Amyotrophic lateral sclerosis (ALS) involves motor neuron loss and shares features with frontotemporal dementia. Understanding ALS heterogeneity is key to developing effective treatments for this neurodegenerative disease.

More Related Videos

Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis
08:59

Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis

Published on: July 16, 2021

3.2K
Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS
12:35

Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS

Published on: March 17, 2012

28.7K

Related Experiment Videos

Last Updated: Mar 1, 2026

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
15:48

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

Published on: July 29, 2007

10.1K
Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis
08:59

Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis

Published on: July 16, 2021

3.2K
Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS
12:35

Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS

Published on: March 17, 2012

28.7K

Area of Science:

  • Neuroscience
  • Genetics
  • Neurology

Background:

  • Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by motor neuron loss.
  • ALS shares significant pathobiological features with frontotemporal dementia (FTD), with many patients exhibiting overlapping symptoms.
  • The etiology of ALS is complex, involving diverse genes and pathophysiological pathways, highlighting the need to address its heterogeneity.

Purpose of the Study:

  • To provide a comprehensive overview of current clinical and diagnostic approaches for ALS.
  • To summarize recent scientific advances in understanding ALS genetics and disease mechanisms.
  • To explore emerging therapeutic strategies and the role of biomarkers in ALS management.

Main Methods:

  • Review of clinical studies and diagnostic criteria for ALS and FTD.
  • Analysis of genetic research identifying key genes and mutations associated with ALS.
  • Examination of various disease models, including cellular and animal models, for ALS research.
  • Evaluation of biomarker discovery and validation studies for ALS.
  • Assessment of preclinical and clinical therapeutic strategies targeting ALS.

Main Results:

  • The heterogeneity of ALS, driven by genetic and molecular diversity, presents a significant challenge for treatment development.
  • Advances in genetic research have identified numerous contributing genes, but a unified understanding of their interplay is still evolving.
  • Biomarker research shows promise for improved diagnosis and monitoring of disease progression.
  • Multiple therapeutic strategies are under investigation, targeting different aspects of ALS pathophysiology.

Conclusions:

  • Effective treatment of ALS requires a personalized approach that accounts for the disease's underlying heterogeneity.
  • Continued research into genetics, biomarkers, and novel therapeutic targets is crucial for advancing ALS care.
  • Understanding the overlap between ALS and FTD may offer new insights into shared disease mechanisms and treatment possibilities.